fludarabine and lysophosphatidic acid

fludarabine has been researched along with lysophosphatidic acid in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gibson, SB; Haney, N; Hu, X; Johnston, JB; Kabore, AF; Kropp, D1
Banerji, V; Gibson, SB; Hu, X; Johnston, JB; Mendoza, FJ; Sun, J1
Brown, M; Gibson, SB; Hernandez, TA; Hu, X; Johnston, JB; Kumar, SA; Kuschak, B1

Other Studies

3 other study(ies) available for fludarabine and lysophosphatidic acid

ArticleYear
Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia cells from apoptosis through LPA receptor activation of the anti-apoptotic protein AKT/PKB.
    The Journal of biological chemistry, 2005, Mar-11, Volume: 280, Issue:10

    Topics: Apoptosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Lysophospholipids; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptors, Lysophosphatidic Acid; Tumor Cells, Cultured; Vidarabine

2005
Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies.
    Cellular signalling, 2008, Volume: 20, Issue:6

    Topics: Apoptosis; Burkitt Lymphoma; Cell Line, Tumor; Gene Expression; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Lysophospholipids; Multiple Myeloma; Mutagens; NF-kappa B; RNA, Messenger; Vascular Endothelial Growth Factor A; Vidarabine

2008
Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:12

    Topics: Aged; Aged, 80 and over; Apoptosis; Cell Line, Tumor; Cell Survival; Cells, Cultured; Female; Gene Expression Profiling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lysophospholipids; Male; Middle Aged; Receptors, Lysophosphatidic Acid; Receptors, Purinergic P2; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Vascular Endothelial Growth Factor A; Vidarabine

2009